MiMedx Group (NASDAQ:MDXG) Announces Earnings Results

MiMedx Group (NASDAQ:MDXG) issued its quarterly earnings results on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $62.28 million for the quarter, compared to analyst estimates of $68.56 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%.

Here are the key takeaways from MiMedx Group’s conference call:

• Surgical revenue grew 9% year over year, with volume increasing in the mid-teens and broad-based growth across placental sheets, particulates, and newer products. Management expects high-single-digit surgical growth in the fourth quarter.
• Total third-quarter sales fell 45% to $62 million, driven by a 71% decline in wound-care revenue following Medicare reimbursement changes. Although wound-care-center volume rose 7% sequentially, management said the market remains difficult to forecast and expects 2027 conditions to resemble 2026.
• Cost reductions and manufacturing improvements helped gross margin improve to 80% and returned the company to positive Adjusted EBITDA of $2 million, a roughly $10 million sequential improvement. Management expects further sequential EBITDA improvement in the fourth quarter and ended the period with $121 million in net cash and no debt.
• MiMedx reached a $25 million patent settlement and licensing agreement, while a federal court vacated the FDA’s adverse classification of AXIOFILL and remanded the matter for further consideration. Two additional patent cases remain active, with management citing favorable claim-construction rulings.
• The FTC issued a second request for information regarding the Sanara MedTech acquisition, delaying the closing timeline and triggering a ticking fee on MiMedx’s proposed $300 million acquisition financing. Management remains committed to the transaction, which it expects would add more than $100 million of revenue, at least $20 million in annual synergies, and an Adjusted EBITDA margin above 20%, but no closing date was provided.

MiMedx Group Stock Performance

MDXG stock traded down $0.28 during midday trading on Thursday, hitting $3.67. 1,392,999 shares of the stock traded hands, compared to its average volume of 1,296,123. MiMedx Group has a 1-year low of $3.03 and a 1-year high of $7.97. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The stock’s fifty day simple moving average is $4.50 and its 200-day simple moving average is $4.31. The firm has a market cap of $534.21 million, a P/E ratio of 91.65 and a beta of 1.18.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Craig Hallum lifted their price target on MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Weiss Ratings upgraded MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, August 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of MiMedx Group in a report on Tuesday, September 15th. Wall Street Zen upgraded MiMedx Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Finally, Raymond James Financial set a $8.00 price target on shares of MiMedx Group in a report on Monday, August 17th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.14.

MiMedx Group Company Profile

MiMedx Group, Inc (NASDAQ: MDXG) is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company’s products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx’s portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.